Ashland (ASH) Expected to Announce Earnings on Tuesday

Ashland (NYSE:ASH) will likely be releasing its earnings data after the market closes on Tuesday, January 28th. Analysts expect Ashland to post earnings of $0.79 per share and revenue of $429,038.33 billion for the quarter. Ashland has set its FY 2025 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Ashland (NYSE:ASH) last posted its quarterly earnings results on Wednesday, November 6th. The basic materials company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.28 by ($0.02). The business had revenue of $522.00 million for the quarter, compared to analysts’ expectations of $524.07 million. Ashland had a return on equity of 7.43% and a net margin of 7.95%. The business’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.41 earnings per share. On average, analysts expect Ashland to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Ashland Stock Down 1.3 %

ASH stock opened at $70.99 on Monday. The company has a market capitalization of $3.34 billion, a P/E ratio of 21.19, a price-to-earnings-growth ratio of 1.14 and a beta of 0.87. Ashland has a 12 month low of $68.14 and a 12 month high of $102.50. The firm’s fifty day simple moving average is $73.63 and its 200-day simple moving average is $82.55. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 1.33.

Ashland Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Saturday, March 15th. Shareholders of record on Saturday, March 1st will be issued a $0.405 dividend. This represents a $1.62 annualized dividend and a yield of 2.28%. The ex-dividend date is Friday, February 28th. Ashland’s payout ratio is 48.36%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ASH. BMO Capital Markets boosted their price objective on Ashland from $83.00 to $84.00 and gave the company a “market perform” rating in a report on Wednesday, December 11th. StockNews.com lowered Ashland from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Wells Fargo & Company dropped their price objective on shares of Ashland from $95.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Insider Buying and Selling

In other Ashland news, VP Eric N. Boni sold 451 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $78.07, for a total transaction of $35,209.57. Following the completion of the sale, the vice president now directly owns 14,182 shares in the company, valued at approximately $1,107,188.74. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Robin E. Lampkin sold 868 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $77.90, for a total value of $67,617.20. Following the completion of the transaction, the senior vice president now owns 2,883 shares in the company, valued at approximately $224,585.70. This trade represents a 23.14 % decrease in their position. The disclosure for this sale can be found here. 1.02% of the stock is owned by insiders.

About Ashland

Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.